Olmesartan · Amlodipine Besylate And Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide

What is Olmesartan?

Olmesartan is an angiotensin II receptor blocker that selectively binds the AT1 receptor in vascular smooth muscle and adrenal gland, competing with angiotensin II and blocking its vasoconstrictor and aldosterone-secreting effects. It is studied in hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Amlodipine Besylate And Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide, NSC-759810, RNH-6270

Drug type

Small molecule

Targets

angiotensin II type 1 (AT1) receptor (AGTR1)

Mechanism

Antagonist of angiotensin II type 1 (AT1) receptor (AGTR1)

Pathways

renin-angiotensin system, aldosterone secretion

Therapy area

Cardiovascular

Developer

Golden State Medical Supply, Inc.

In trials of

ALNY

FDA status

Approved as Amlodipine Besylate And Olmesartan Medoxomil, Olmesartan Medoxomil-Hydrochlorothiazide, NDA022100 · FDA label

UNII

8W1IQP3U10

✅ FDA-approved uses

• Hypertension (Amlodipine Besylate And Olmesartan Medoxomil)

From the indications section of the FDA label (version of Apr 28, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertension

Other drugs acting on AGTR1

Sources

• FDA label (DailyMed)
• FDA label Amlodipine Besylate And Olmesartan Medoxomil (2026-04-28), indications
• FDA label Olmesartan Medoxomil-Hydrochlorothiazide (2026-01-19), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT05103332

Updated Oct 11, 2026.